TheraRadar
Clinical-Stage Companies / Thirty Respiratory Limited

Thirty Respiratory Limited

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 10/13/2025

6
Total Trials
2
Phase 3
6
Phase 2
2
Recruiting
81
Score

Pipeline by Phase

Phase 3
2
Phase 2
6
Phase 1
1

Therapeutic Focus

Non-Cystic Fibrosis Bronchiectasis Pulmonary Tuberculoses Rifampicin Susceptible Pulmonary Tuberculosis COPD Bronchiectasis

Clinical Trials (6)

NCT07073638 Phase 2 RECRUITING

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

Started: 10/13/2025

NCT06041919 Phase 2 TERMINATED

Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

Started: 9/27/2023

NCT04858451 Phase 2 TERMINATED

COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2

Started: 3/1/2021

NCT04842331 Phase 2 WITHDRAWN

PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)

Started: 9/1/2021

NCT04460183 Phase 2 COMPLETED

A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19

Started: 7/29/2020

NCT06663176 Phase 1 ACTIVE NOT RECRUITING

Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)

Started: 10/16/2024

Drug Candidates

RESP302 RESP303 RESP30TB HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) RESP301 HRZE RESP301 (a nitric oxide generating solution) RESP301, a Nitric Oxide generating solution
Activity Status: Slowing
Last Trial Started: 10/13/2025
Last Trial Ended: 3/6/2025
Trials (12 months): 0
Completed Trials: 1
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.